Loading...
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Corrie, P Matin, R Gupta, Avinash Qian, W Wordsworth, S Gibbons, E Chhabra, A Harman, C Mather, C Middleton, M
Corrie, P
Matin, R
Gupta, Avinash
Qian, W
Wordsworth, S
Gibbons, E
Chhabra, A
Harman, C
Mather, C
Middleton, M
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 90.6 KB
Keywords
Type
Meetings and Proceedings
Citation
Corrie PG, Matin RN, Gupta A, Qian W, Wordsworth S, Gibbons E, et al. 1300TiP A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM). Ann Oncol. 2018;29(suppl_8):464.